Abstract | A key event in atherosclerosis is a maladaptive inflammatory response to subendothelial lipoproteins. A crucial aspect of this response is a failure to resolve inflammation, which normally involves the suppression of inflammatory cell influx, effective clearance of apoptotic cells and promotion of inflammatory cell egress. Defects in these processes promote the progression of atherosclerotic lesions into dangerous plaques, which can trigger atherothrombotic vascular disease, the leading cause of death in industrialized societies. In this Review I provide an overview of these concepts, with a focus on macrophage death and defective apoptotic cell clearance, and discuss new therapeutic strategies designed to boost inflammation resolution in atherosclerosis.
. These processes are mediated by a wide array of molecules, including antiinflammatory cytokines, lipoxygenase-derived bioactive lipids and transcription factors. Inflammation resolution also involves subsets of immune cells, such as alternatively activated macrophages (M2 macrophages), that have specific functional characteristics related to suppressing inflammation and engulfing cellular debris 3 . Understanding the principles of inflammation resolution is important to determine the complex process of atherosclerosis progression. Atherothrombotic vascular disease (ATVD) is the most frequent cause of death in the industrialized world, and this problem is growing owing to the worldwide increase in obesity and insulin resistance 4 . Insulin resistance is thought to be a major risk factor for ATVD owing to both its effects on systemic risk factors, such as plasma lipoprotein levels and blood pressure, and direct effects on the arterial wall 5 . Atherogenesis is triggered by the retention of apo lipoprotein B-containing lipoproteins in the sub endothelium of the arterial wall [6] [7] [8] 
. These retained lipoproteins, perhaps after oxidative modification, trigger a chronic inflammatory response that initially involves monocyte-derived macrophages and then involves other inflammatory cells, including T cells and mast cells [6] [7] [8] . In the early stages of disease development, the atherosclerotic lesions are small and asymptomatic and are not at risk of causing atherosclerotic plaque disruption and luminal thrombosis. Moreover, at least one key event in inflammation resolution -efferocytosis -seems to function normally in these early lesions (see below). However, the few lesions that do progress to the type of dangerous atherosclerotic plaque that can cause ATVD have all the hallmarks of defective resolution of inflammation, including defective efferocytosis, a persistent inflammatory state and defective egress of inflammatory cells [9] [10] [11] [12] (FIG. 1) . Defects in any of these processes promote the formation of highly inflamed and necrotic plaques that are referred to as 'vulnerable plaques' because they are vulnerable to structural disruption and atherothrombosis, which are the immediate precursors of acute cardiovascular clinical events 13 . For example, the failure of macrophage egress leads to prolonged production of collagen-degrading matrix proteases and coagulation-promoting tissue factor by these cells 7, 8 . The failure of efferocytosis leads to post-apoptotic secondary necrosis, which amplifies the inflammatory response and eventually leads to the generation of the plaque-disrupting necrotic core of vulnerable plaques 9, 10 . In this Review, I discuss the processes of immune cell entry and egress, the anti-inflammatory signalling induced through mediators of inflammation resolution and the role of macrophage death and defective efferocytosis in plaque progression.
Efferocytosis
The phagocytic clearance of apoptotic cells (from the Latin 'effero', meaning to take to the grave or bury) before they undergo secondary necrosis. The process usually triggers an anti-inflammatory response.
Alternatively activated macrophage (M2 macrophage).
A macrophage stimulated by IL-4 or IL-13 that expresses arginase 1, the mannose receptor CD206 and IL-4 receptor-α. There may be pathogen-associated molecular patterns expressed by helminths that can also drive the alternative activation of macrophages.
Macrophage death and defective inflammation resolution in atherosclerosis Atherosclerosis
A process whereby lipids, inflammatory cells and extracellular matrix accumulate in the subendothelial space (intima) of focal areas of medium-sized arteries, which finally leads to plaque formation.
Atherothrombotic vascular disease
(ATVD). Disease caused by acute occlusive arterial thrombosis overlying areas of chronic atherosclerosis. The occlusive thrombosis starves the tissue that the involved artery feeds of oxygen and nutrients. For example, if the involved artery feeds the heart muscle, myocardial infarction (death of heart muscle cells) can ensue.
Insulin resistance
A state in which signalling through insulin receptors is impaired. The cause can be exposure to high levels of insulin, which downregulates insulin receptors by a negative homeostatic mechanism, or disruption of signalling molecules downstream of the insulin receptor, such as insulin receptor substrate 1 (IRS1) and IRS2. Insulin resistance, caused by high levels of insulin in the bloodstream, is responsible for a substantial portion of the pathology associated with type 2 diabetes, including ATVD.
Atherosclerotic plaque
The name given to an atherosclerotic lesion without precise designation of lesion stage, but usually referring to a lesion that has developed beyond the early foam cell stage, particularly a lesion that is raised and fibrotic.
Atherothrombosis
Following the rupture of unstable atherosclerotic plaques, thrombogenic material becomes exposed or released to mediate thrombus formation and eventually occlusion of an artery.
Monocyte entry and macrophage egress
Two key processes in the resolution phase of inflammation are the decreased entry of new inflammatory cells and the egress of cells from the site of inflammation 1, 12 . However, the entry of monocytes into preexisting inflammatory atherosclerotic lesions in mice is enhanced (instead of suppressed as would normally occur during inflammation resolution) 14 . Moreover, numbers of ly6C hi monocytes, which are precursors of inflammatory macrophages, increase in the blood during hypercholesterolaemia in mice, in part owing to their impaired conversion into less inflammatory ly6C low monocytes 15 . These studies suggest that there is persistent recruitment of inflammatory monocytes to established atherosclerotic lesions, particularly during hypercholesterolaemia, which is consistent with defective inflammation resolution.
Monocytes can differentiate into two main types of macrophages: those that promote inflammation, which are referred to as classically activated (M1) macrophages, and M2 macrophages, which promote resolution of inflammation 3 . Thus, an imbalance in the ratio of M1 and M2 macrophages in advanced atherosclerosis may cause or at least reflect impaired resolution. Among the factors that can shift the balance in favour of M2 macrophage differentiation are an increase in T helper 2 (T H 2) cell-secreted molecules, such as interleukin-4 (Il-4) 3 , the transcription factors peroxisome proliferator-activated receptor-γ (PPARγ) and PPARδ 16, 17 , and the bioactive lipid sphingosine 1-phosphate (S1P) 18 . Studies in mice have shown that processes that promote T H 2 cell polarization 19 , activate PPARγ 20 or activate SIP signalling 18 have beneficial effects on atherosclerosis, but the degree to which these results reflect M2 macrophage polarization, other aspects of inflammation resolution or other processes in atherogenesis remains to be fully explored.
egress of inflammatory cells from atheroma is also impaired 21 . An important step in the egress of inflammatory myeloid cells is their conversion into migratory cells, such as dendritic cells (DCs) 22 . Many growth factors and cytokines (such as granulocyte-macrophage colonystimulating factor (GM-CSF), tumour necrosis factor (TnF), Il-4 and Il-6) have been shown to promote DC differentiation and/or maturation, perhaps forming a link between the initial inflammatory cytokine stage and the subsequent resolution stage of inflammation 23 . In the atherosclerotic lesions of apolipoprotein E (Apoe) -/-mice, a model of atherosclerosis, inflammatory cell egress is not observed in the setting of hypercholesterolaemia. However, when plaques are exposed to low levels of cholesterol through transplantation of plaque-bearing aortae from the Apoe -/-mice into wild-type mice, DC-like cells migrate through adventitial lymph vessels to local lymph nodes in a process that is dependent on the DC migratory molecule CC-chemokine receptor 7 (CCR7) (REF. 24) . Although the quantitative importance of this DC egress pathway is not yet known, these data suggest that one factor that impairs key processes of inflammation resolution is the hypercholesterolaemic state, perhaps through the induction of inflammatory molecules that block the resolution phase.
Inflammation-resolving mediators
Anti-inflammatory cytokines, signalling molecules and transcription factors have important roles in the resolution of inflammation 1, 2 . The most important of these are Il-10; transforming growth factor-β (TGFβ); lipid mediators such as lipoxins, resolvins, protectins, maresins and prostaglandins; and, in the case of macrophages in atherosclerosis, liver X receptors (lXRs) and the PPAR transcription factors [25] [26] [27] [28] [29] [30] . The main target cells of Il-10 are macrophages and DCs, in which Il-10 receptor signalling
Box 1 | How atherosclerotic plaques develop
Certain areas of medium-sized arteries are prone to the permeation and then subendothelial accumulation of apolipoprotein B-containing lipoproteins, such as low-density lipoprotein and remnant lipoproteins 6 . For reasons that are not completely understood, but are probably related to an initial innate immune response to the accumulated and often subendothelially modified lipoproteins, the overlying endothelium is activated to secrete chemokines and express adhesion molecules that attract and bind monocytes 7, 8 . These processes are followed by entry of the monocytes into the subendothelial space. Once in the subendothelium, the monocytes differentiate into macrophages and ingest the retained lipoproteins [6] [7] [8] . Lipoprotein uptake promotes the intracellular accumulation of various lipids, including cholesterol, oxysterols and fatty acids, which promotes the accumulation of lipid droplets in the cytoplasm of macrophages. This accumulation causes the macrophages to become foam cells and induces an inflammatory response [6] [7] [8] . Over weeks, months and even years, the process continues and even amplifies. For example, foam cells can secrete additional extracellular matrix molecules that further promote lipoprotein retention, and the inflammatory response leads to the recruitment of more monocytes, as well as T cells, mast cells and possibly neutrophils [6] [7] [8] . The lesion enlarges, but at this stage the arterial lumen remains large enough to feed the distal organ owing to outward remodelling of the arterial wall. Moreover, in most cases, the lesion is contained by a subendothelial scar-like structure referred to as the fibrous cap, which is produced by collagen-secreting myofibroblasts that populate the intima and are derived from precursor cells in the media, adventitia and/or blood 7, 8 . However, some of these lesions undergo a process of arterial wall breakdown. The types of lesions that are susceptible to this process of arterial wall breakdown are often referred to as 'vulnerable plaques' and are characterized by large areas of necrosis, thin fibrous caps and a heightened state of inflammation 13 . Disruption of the intima can expose pro-coagulant and pro-thrombotic contents within the intima, such as tissue factor, to coagulation factors and platelets in the blood 7, 8 .
In the worst-case scenario, an occlusive thrombus forms, leading to acute oxygen and nutrient deprivation of distal tissues fed by the artery. When these events occur in the coronary arteries, the region of heart muscle tissue fed by the involved artery becomes injured, and the result is unstable angina, myocardial infarction or sudden cardiac death. induces the expression of the anti-inflammatory molecule suppressor of cytokine signalling 3 (SoCS3) and inhibits the nuclear factor-κB (nF-κB) pathway 25 . The net result is the suppression of macrophage-mediated activation of inflammatory T cells and decreased production of pro-inflammatory cytokines (Il-1, Il-6, Il-12 and TnF) and matrix metalloproteinases by macrophages. Il-10 also activates signal transducer and activator of transcription 3 (STAT3), which inhibits endoplasmic reticulum (ER) stress-induced apoptosis in macrophages by inducing the expression of cell-survival molecules 31 . Il-10 can also enhance efferocytosis both in vitro and in vivo 32 . when fat-fed low-density lipoprotein receptor (Ldlr) -/-mice, which develop hypercholesterolaemia and atherosclerotic plaques, were transplanted with Il-10-transgenic bone marrow cells, there was a 47% decrease in the atherosclerotic lesion size and an 80% decrease in the necrotic core area compared with mice that received wild-type bone marrow cells 33 . Moreover, Il-10 levels in the serum are lower in humans with acute coronary syndromes and inversely correlate with future atherothrombotic events in survivors of myocardial infarction 34 . Thus, deficiency in the amounts and/or functions of Il-10 may contribute to the defect in inflammation resolution in atherosclerosis.
TGFβ has two key roles in inflammation resolution: suppression of inflammation, particularly as mediated by CD4 + CD25
+ regulatory T cells and by phagocytes during the process of apoptotic-cell clearance 35, 36 , and stimulation of a protective 'scar' response in resolving lesions by inducing collagen production by fibroblasts 37 . A defect in the protective scar response in intimal myofibroblastlike smooth muscle cells may contribute to a key feature of vulnerable atherosclerotic plaques, namely thinning of the fibrous cap 13 . when TGFβ signalling was interrupted in Apoe -/-mice by administration of a decoy soluble TGFβ receptor or TGFβ-specific neutralizing antibodies, plaque progression towards a vulnerable phenotype was accelerated and was associated with a heightened state of inflammation, large necrotic cores and thin fibrous caps 38, 39 . By contrast, transgenic overexpression of TGFβ in Apoe -/-mice stabilized atheroma by decreasing these three detrimental end points 37 .
A recent study has suggested that macrophage 12,15-lipoxygenase, an enzyme that is involved in arachidonate metabolism, has a role in lesional inflammation resolution in Apoe -/-mice through the synthesis of the pro-resolving lipid mediators lipoxin A4, resolvin D1 and protectin D1 (REF. 11 ). In particular, 12,15-lipoxygenase deficiency promoted lesion formation, and an inverse correlation between 12,15-lipoxygenase expression and blood level of certain inflammatory cytokines was observed. In vitro experiments showed that lipoxin A4, resolvin D1 and protectin D1 suppressed the production of atherosclerosis-associated inflammatory cytokines by lipopolysaccharide (lPS)-activated macrophages and enhanced the ability of macrophages to ingest apoptotic cells 11 . Moreover, TnF-mediated activation of endothelial cells, which has a crucial role in monocyte chemotaxis and adhesion during atherogenesis, was also suppressed by lipoxin A4 and resolvin D1 (REF. 11 ). other models have substantiated these findings. For example, in a rabbit model of inflammatory periodontal disease, which is a significant risk factor for ATVD in humans 40 , overexpression of 15-lipoxygenase (the rabbit enzyme involved in lipoxin biosynthesis) and the subsequent production of lipoxin A4 were associated with a decrease in high-fat-diet-induced atherosclerosis 41 . In addition to the 12,15-lipoxygenase pathway, there is evidence that a 14-lipoxygenase pathway can generate maresin (macrophage mediator in resolving inflammation), which has potent anti-inflammatory effects 28 . The cyclooxygenase pathway can also participate in inflammation resolution 27, 42 . For example, in lPS-stimulated human macrophages in vitro, prostaglandin e 2 (PGe 2 ) interaction with the eP4 receptor suppressed the expression of inflammatory cytokines and chemokines 43 . This effect was shown to be independent of the canonical eP4-cyclic AMP-protein kinase A pathway 43 , but other anti-inflammatory effects of PGe 2 involve cAMP-protein kinase A-mediated induction of Il-10 and suppression of nF-κB 44 . Macrophage eP4 deficiency in high-fat-diet-fed Ldlr -/-mice is associated with a decrease in phosphorylated AkT family members and an increase in early lesional macrophage apoptosis 45 , suggesting that the predominant effect of the macrophage PGe 2 -eP4 pathway in this context is induction of an AkT-mediated cell survival pathway.
Another mediator of inflammation resolution, and one that has particular relevance to atherosclerosis, is the lXR family of transcriptional activators. lXRs have antiinflammatory effects in macrophages 29, 46 , which include inhibition of nF-κB-mediated gene induction (such as of pro-atherogenic Il-6), suppression of antigen-induced T cell proliferation and suppression of matrix metalloproteinase 9 production (which is thought to mediate plaque disruption) 47 , 48 . lXR activation is also involved 
Periodontal disease
A bacteria-mediated inflammatory disease of the gums that has an epidemiological association with atherothrombotic vascular disease, perhaps through promoting systemic inflammation.
in a key step in atherosclerosis regression, namely cholesterol efflux from cholesterol-loaded macrophages 49, 50 . In mouse models of atherosclerosis, lXR agonists markedly suppress lesion progression, even after lesions have become established, and deletion of Lxr promotes lesion progression [51] [52] [53] . Importantly, the various cellular processes of inflammation resolution can be linked by these inflammationresolving factors (FIG. 2) . For example, Il-10 not only directly blocks inflammatory responses in M1 macrophages but also stimulates the conversion of M1 macrophages to the M2 subtype and enhances efferocytosis 3 . efferocytosis, in turn, promotes further Il-10 production 36 . lXR activation in macrophages links two key features of inflammation resolution: suppression of inflammatory cytokine production 29 and enhancement of efferocytosis through the induction of at least two efferocytosis receptors, transglutaminase 2 (encoded by TGM2) and proto-oncogene tyrosine-protein kinase MeR (MeRTk) 54, 55 . As a third example of integration, successful efferocytosis leads to the production of TGFβ 36 , which stimulates the formation of the protective fibrous cap in atheroma 37 . 12,15-lipoxygenase not only leads to the synthesis of lipid mediators of inflammation resolution, including those that enhance efferocytosis 26 , but also mediates the induction of lipids, such as 13-hydroxyoctadecadienoic acid (13-HoDe) and 15-hydroxyeicosatetraenoic acid , that are activators of anti-inflammatory PPARγ 30 . In this regard, PPARγ itself is induced by Il-4, which promotes the formation of M2 macrophages 3 .
Macrophage death and efferocytosis
Early lesional macrophage death. Although the mechanisms of macrophage death in early lesions are not well known, apoptosis occurs in macrophage-rich regions of early lesions 56 . Several studies have used genetic engineering in mouse models of atherosclerosis to either increase or decrease macrophage apoptosis in early lesions, and these studies have shown that apoptosis in this setting is associated with smaller lesion size and less plaque progression 45, [57] [58] [59] [60] . A likely explanation for this phenomenon is that apoptotic cells are efficiently cleared by neighbouring macrophages in early lesions and therefore the lesions would have fewer inflammatory cells and post-apoptotic necrotic cells, as well as more efferocyte-derived antiinflammatory mediators. Support for this concept comes from a study in which the efferocytosis mediator complement component 1q (C1q) was genetically targeted in Ldlr -/-mice 61 . In these mice, the appearance of apoptotic macrophages in early lesions increased dramatically, suggesting that the normal paucity of detectable apoptotic cells in early lesions is due to efficient efferocytosis. Activation of another family of transcription factors, the liver X receptors (LXRs), links two key features of inflammation resolution: suppression of inflammatory cytokine production and enhancement of efferocytosis. Successful efferocytosis leads to the production of transforming growth factor-β (TGFβ), which stimulates formation of scar tissue in wound healing during inflammation resolution and the protective fibrous cap in atheroma. The corollary of this concept is that the elements of defective inflammation resolution known to exist in advanced lesions, notably defective efferocytosis, have not yet taken hold in early atherosclerosis 9, 10 (FIG. 3a) .
Nature Reviews
Advanced lesional macrophage death. Several hypotheses have been proposed to explain macrophage apoptosis in advanced lesions, and undoubtedly more than one mechanism is involved. examples include growth factor deprivation and the presence of toxic cytokines and oxidized lipids or lipoproteins 62 , but there is currently little evidence for these hypotheses in vivo. However, there is increasing in vivo evidence supporting the concept that eR stress may contribute greatly to advanced lesional macrophage death (FIG. 3b) . eR stress activates a branch of the unfolded protein response (UPR) pathway that increases the expression of the pro-apoptotic protein CeBP-homologous protein (CHoP; also known as DDIT3) 63 . The expression of CHoP can lead to apoptosis by several mechanisms, but recent work points to a specific apoptotic mechanism that involves release of Ca 2+ from the eR lumen 64, 65 . There are many eR stressors present in advanced atherosclerotic lesions, and expression of eR stress proteins -including CHoP -is closely correlated with apoptosis and plaque vulnerability in human coronary arteries 66 . In vitro studies have suggested that some of these atherosclerosis-relevant eR stressors, such as 7-ketocholesterol, are sufficient by themselves to trigger this apoptotic pathway if they are present in sufficient amounts 64 . However, in cases of more subtle eR stress a second signal is needed to trigger apoptosis 67, 68 . An example includes excess accumulation of lipoprotein-derived cholesterol by macrophages, in which the eR stress signal arises from excess cholesterol accumulation in the eR membrane, and the second signal is engagement of pattern recognition receptors (PRRs), which enhance pro-apoptotic processes and suppress compensatory cell-survival signalling in the setting of eR stress 67, 68 . There are in vivo molecular-genetic causation data supporting these concepts. Although mouse models of atherosclerosis, such as high-fat-diet-fed Apoe -/-and Ldlr -/-mice, are not useful for studying plaque disruption or acute atherothrombosis, they are valuable for studying atherosclerosis up to and including the stage of plaque necrosis 69 . Using these models, it has been possible to test the pathophysiological relevance of specific mechanisms of macrophage apoptosis, as well as the suggestion that advanced lesional macrophage death promotes plaque necrosis (TABLE 1) . For example, advanced lesional macrophage apoptosis and plaque necrosis are reduced in a mouse model with a heterozygous mutation in Npc1 (which facilitates eR stress in the setting of excess cholesterol), and in mice with null mutations in Stat1 (which is a key pro-apoptotic signalling molecule downstream of the eR stress and PRR pathway), Chop, or Sra1 and Cd36 (which encode PRRs that can serve as second signals for eR stress-induced apoptosis) [70] [71] [72] [73] . Moreover, in the context that insulin resistance is a major risk factor for ATVD in industrialized societies 4,5 , activation of the macrophage eR stress-apoptosis pathway, advanced lesional macrophage apoptosis and plaque necrosis are enhanced in the setting of macrophage insulin resistance 74, 75 . Finally, apoptotic processes in general, and eR stress-induced apoptosis in particular, usually results from an imbalance between apoptotic and compensatory cell-survival pathways. For example, eR stress Figure 3 | Efferocytosis and inflammation resolution in early and advanced atherosclerosis. a | In early atherosclerotic lesions, efferocytosis is efficient, leading to rapid clearing of apoptotic macrophages. This process prevents secondary necrosis, elicits the production of anti-inflammatory cytokines and clears macrophages from the lesions. The result of this inflammation resolution process is decreased plaque progression. b | In advanced lesions, efferocytes do not function properly and thus apoptotic macrophages, which arise in part from endoplasmic reticulum (ER) stress-induced apoptosis, become secondarily necrotic. The necrotic material is a stimulus for inflammation, and the normal anti-inflammatory signalling associated with efferocytosis does not occur. Moreover, an important mechanism for ridding the lesion of inflammatory macrophages is lost. Thus, inflammation resolution fails to occur normally, and necrotic macrophages coalesce into necrotic cores. These features define plaques that are vulnerable to rupture, which in turn can trigger acute lumenal thrombosis and arterial occlusion. IL-10, interleukin-10; TGFβ, transforming growth factor-β.
activates the mitogen-activated protein kinase p38 family, which promote cell survival in certain settings of eR stress by activating Akt family members, known mediators of cell survival 76 . Macrophage-targeted knockout of p38α in Apoe -/-mice enhanced both advanced lesional macrophage apoptosis and plaque necrosis 76 . Advanced plaques in humans also show markers of eR stress and evidence of macrophage apoptosis [77] [78] [79] . In one study, autopsy specimens and fresh atherectomy specimens of human coronary arteries from patients with heart disease were divided into five stages of atherosclerosis, from very early lesions to vulnerable plaques, and analysed for UPR markers and apoptosis. The results showed a close correlation between UPR marker expression (including CHoP), apoptosis and advanced plaque morphology 78 . These correlative findings set the stage for genetic studies, such as genome-wide association studies, to identify a more causative relationship between genes in the eR stress-apoptosis pathway and human coronary artery disease.
Efferocytosis.
A key step in the resolution of inflammation is efferocytosis of apoptotic inflammatory cells 36, 80 . In acute inflammation, this process mostly involves the clearance of short-lived apoptotic neutrophils. However, in the chronic inflammatory process of atherosclerosis, most of the apoptotic cells that need to be cleared are apoptotic macrophages 9, 61 . efficient clearance of apoptotic cells prevents secondary necrosis and triggers an anti-inflammatory response through the induction of TGFβ, Il-10 and other anti-inflammatory cytokines 80 . Inflammation can also be suppressed in phagocytes by molecules released by the apoptotic cells themselves, such as protein S100A9 released by apoptotic neutrophils 81 . of relevance to ATVD, uncleared apoptotic cells also shed plasma membrane microparticles, which can stimulate thrombosis 82 . In early atherosclerotic lesions, as mentioned previously, efferocytosis seems to be efficient. In advanced lesions, however, increased apoptosis is associated with plaque necrosis, which suggests inefficient efferocytosis 9, 10 (FIG. 3b) . Indeed, a clear Apoe, apolipoprotein E; Chop, CEBP-homologous protein (also known as Ddit3); Cre, cre recombinase; ER, endoplasmic reticulum; Insr, insulin receptor; Ldlr, low-density lipoprotein receptor; Lysm, lysozyme M; Mertk, proto-oncogene tyrosine-protein kinase MER; Mfge8, milk fat globulin E8; Npc1, Niemann-Pick C1 protein; Sra, type A scavenger receptor; Stat1, signal transducer and activator of transcription 1; Tg2, transglutaminase 2. *This designation indicates transplantation of bone marrow from mutant mice into lethally irradiated Apoe -/-or Ldlr -/-mice to create chimeric mice in which only bone marrow-derived cells carry the mutation. Bone marrow cells from wild-type mice are used to generate control mice. Using this method, the main type of lesional cell carrying the mutation is the macrophage. ‡ fl/fl refers to both alleles of the indicated gene being flanked by loxP sites. §
Mertk
KD is a kinase domain mutation of the MERTK protein.
Foam cell
A macrophage in the arterial wall that ingests cholesterolrich apolipoprotein Bcontaining lipoproteins and thereby accumulates cholesteryl fatty acid esters. These cells secrete various substances involved in plaque growth.
defect in efferocytosis in advanced human atherosclerotic lesions compared with a control tissue (human tonsils) was revealed by a study in which in situ efferocytosis was assessed through quantification of apoptotic cells that were either associated with or free from neighbouring phagocytes in these tissues 83 . what are the molecular mechanisms of efferocytosis in advanced atheroma? And what goes wrong in this setting? efferocytosis involves a complex interplay between several sets of proteins that enable the recognition and engulfment of apoptotic cells by phagocytes 80, 84 . In the early stages of apoptosis, cells secrete factors, referred to as 'find me' signals, that attract phagocytes (for example, lysophosphatidylcholine 85 ), and they suppress the secretion of other molecules, referred to as 'don't eat me' signals, that normally prevent the phagocytosis of non-apoptotic cells (for example, CD47 (REF. 86) ). Apoptotic cells also express a unique set of surface molecules that recognize and bind to cognate receptors on the apoptotic cell (for example, phosphatidylserine 87 ). In several cases, the interaction between the surface molecule and receptors involves an intermediary bridging molecule. For example, αVβ3 integrin and MeRTk on phagocytes interact with apoptotic cells through the bridging molecules milk fat globulin e8 (MFGe8; also known as lactadherin) and growth arrest-specific protein 6 (GAS6), respectively 80, 84 . Contact between apoptotic cells and phagocytes enables engulfment of the apoptotic cells, leading eventually to digestion in phagolysosomes. In addition, as mentioned above, receptor engagement on the phagocyte often triggers an anti-inflammatory response 36, 80 . Mouse studies have revealed specific roles for several efferocytosis receptors or bridging molecules in advanced atherosclerosis, including transglutaminase 2 (REF. 88 (TABLE 1) . For example, Apoe -/-mice lacking MeRTk have a defect in efferocytosis in advanced atheroma that correlates with an increase in plaque inflammation and plaque necrosis 90, 91 . what seems to be defective efferocytosis in advanced atheroma could, in theory, instead be extensive apoptosis that overwhelms the phagocytic capacity of macrophages. However, the normal high capacity of macrophages for efferocytosis, including that seen in early atherosclerotic lesions, suggests that this is, at most, only part of the explanation 59, 80 . A second possibility is that advanced lesional macrophage death per se limits efferocytosis by limiting the pool of competent efferocytes. However, advanced lesions have a large population of macrophages that could presumably carry out this role 93 . Furthermore, even when macrophages accumulate large amounts of cholesteryl fatty acid esters and become foam cells, which is a common feature of lesional macrophages, their ability to recognize and engulf apoptotic cells is not compromised 94 . In addition, efferocytes possess a remarkable ability to remain viable even after they engulf apoptotic cells that are extremely rich in potentially toxic cholesterol, because the process of efferocytosis activates several cholesterol efflux and cell survival pathways that protect the cells 95 . A third possibility is that advanced lesional apoptotic macrophages are poor substrates for efferocytic recognition and engulfment. For example, the nature of the apoptotic stimulus or some other feature in these lesions might lead to poor display of efferocytosis ligands or find me signals and/ or inappropriately increased expression of don't eat me signals on the apoptotic cells. A fourth possibility is that expression or function of bridging molecules or effero cytosis receptors is deficient in atheroma. In this context, MeRTk is susceptible to sheddase-mediated cleavage, leading to release of the extracellular portion of the receptor, which is referred to as soluble MeR 96 . MeRTk cleavage inhibits efferocytosis by two mechanisms -destruction of MeRTk and competitive inhibition of efferocytosis by soluble MeR 96 . As another example, the expression of the bridging molecules GAS6 and MFGe8 may be downregulated in advanced lesions by the processes of lesional smooth-muscle cell death and inflammation, respectively 97 . There may also be inappropriate activation of negative regulators of efferocytosis, such as a recently discovered lipid phosphatase called myotubularin 98 . Some of these changes in efferocyte function may be related to alterations in phagocyte subpopulations in advanced lesions: that is, an increase in DCs, which are less efficient at clearing apoptotic cells than macrophages 99 , or an increase in the ratio of M1/M2 macrophages 3 . In this context, a deficiency in PPARδ and/or its activators in advanced lesions could increase the M1/M2 ratio and decrease efferocytosis 100, 101 . Defective efferocytosis may also be associated with the ageing process, which is a major risk factor for ATVD 102 . For example, clearance of apoptotic cells is defective in the tissues of aged mice and in isolated DCs from elderly humans 103, 104 . The mechanism of this defect is not known, but the defect in the mouse study could be reproduced in vitro by exposure of macrophages from young mice to serum from old mice, suggesting the presence of an efferocytosis-inhibitory factor or the absence of a soluble efferocytosis effector in the aged mouse serum 103 . In the human DC study there was a general defect in phagocytic signalling 104 . Finally, to the extent that some degree of efferocytosis does occur in advanced lesions, a crucial component of antiinflammatory signalling may be defective, for example owing to a defect in secretion of, or response to, antiinflammatory cytokines. whatever the mechanisms, increasing evidence suggests that defective efferocytosis in advanced atheroma is a major cause of necrotic core formation and thus contributes substantially to the formation of vulnerable plaques.
Future directions and therapeutic implications
The ability to translate the complex process of plaque progression into an integrated molecular and cellular concept of defective inflammation resolution provides a useful way to understand how atherosclerosis leads to clinical disease and how plaque progression may be prevented by new therapeutic approaches. In this context, it is important to outline areas within this paradigm that need further investigation. Most importantly, we need a more complete understanding of the molecular and cellular mechanisms for defective inflammation resolution in advanced atherosclerosis. Although this Review has focused on upstream mediators of inflammation resolution, complex negative feedback mechanisms at the transcriptional and translational levels are crucial sequelae of the inflammatory response 105, 106 . At a fundamental level, it will be important to elucidate what portion of the defect in inflammation resolution in advanced atherosclerosis is due to defective production of inflammation-resolving effectors and what portion is due to the defective function of these effectors at the cellular level; for example, decreased activity of receptor signal transduction pathways.
now that we possess a reasonably complete list of these effectors, and with a good knowledge of how they act on cells, we can probe plaques during the most important period of progression to the necrotic (thin fibrous cap) stage for transcription factors and enzymes involved in effector formation and for the receptors and signalling molecules that are activated by these effectors. A good knowledge of the cell types involved is also crucial, and more work is needed in this area. T cells are involved in the production of certain inflammationresolving effectors, such as Il-10, and in the production of factors that regulate the function of these effectors. For example, T H 2-and T H 1-type cytokines influence the balance between M2 and M1 macrophages, respectively 3 . The main inflammation resolution effector cells in lesions are macrophages and DCs, and understanding how each of the various subsets of these cell types influences the overall resolution response -and the defects of these cells in advanced lesions -is an important goal for the future. Moreover, it will be interesting to assess the roles of mast cells and neutrophils in normal and defective inflammation resolution, because studies are increasingly implicating these two cell types in atherogenesis and plaque progression 107, 108 . The answers to these questions will increasingly inform the field as to the best therapeutic approaches to prevent defective inflammation resolution in progressing atherosclerotic plaques and to reverse the defect in those plaques that are already advanced. on the basis of our current knowledge, we can begin to propose strategies. with regard to lipid mediators of inflammation resolution, omega-3 long-chain fatty acids, which occur naturally in fish oils, are precursors of protectins, resolvins and maresins 26, 28 , and the fish oil eicosapentaenoic acid has been shown to have beneficial effects on ATVD in humans 109 . More in-depth understanding of the mechanisms of these effects may suggest more specific and potent drugs to enhance inflammation resolution in advanced atherosclerotic lesions. In this context, exposure of macrophages to saturated fatty acids in vitro and exposure of obese mice to a saturated fatty acidenriched diet led to defects in macrophage efferocytosis, including in advanced atherosclerotic lesions, and one mechanism may be the displacement of the omega-3 fatty acids in macrophages by the saturated fatty acids 110 . Activators of lXRs and PPARs are already available as oral-based formulations, although off-target systemic effects, notably hepatosteatosis and heart failure, respectively, limit their current usefulness 47 . As another example, the orally available drug FTy720, a mimetic of the pro-resolution lipid S1P, has been shown to increase the proportion of M2 macrophages in atherosclerotic lesions and slow the lesion progression in mice 18 . In a mouse model of peritonitis, an analogue of the pro-resolution lipid lipoxin A4 enhanced efferocytic clearance of apoptotic neutrophils 111 . endogenous and exogenous cannabinoids, which are fatty acid derivatives, can trigger inflammation resolution, perhaps through stimulation of the biosynthesis of lipid mediators 112 . Indeed, oral administration of the cannabinoid receptor 1 agonist rimonabant suppressed atherosclerosis and plaque inflammation in high-fat-diet-fed Ldlr -/-mice 113 . However, there are significant side effects to rimonabant 114 and so, as with lXR and PPAR agonists, the safest application of these potent agents would be in a setting that optimizes the specific accumulation of the drug in atherosclerotic plaques. Thus, future developments in plaque-targeted drug technology will be important with these agents.
Therapeutic administration of bioactive proteins is an even greater technical challenge but one with great promise. For example, causation data in mice and genetic association data in humans suggest that the inflammation-resolving effectors Il-10 and TGFβ can prevent plaque progression 33, 34, [37] [38] [39] . The protein annexin I, which is an anti-inflammatory downstream effector molecule of glucocorticoids, has been shown to increase the efferocytosis of apoptotic neutrophils in the inflamed joints of a mouse model of systemic lupus erythematosus 115 . The challenge in these cases is how to administer a bioactive protein and how to do it in a plaque-targeted manner. new approaches in plaque-targeted protein delivery systems, such as nanoparticle-based therapy, may offer great promise in this area 116 . A different type of innovative strategy to enhance efferocytosis was suggested by Silverman and colleagues 117 , who showed that immunization of mice with apoptotic cells boosted the production of natural IgM antibodies to apoptotic cell surface proteins, leading to C1q recruitment and increased efferocytosis. others have suggested that if efferocytosis could be enhanced, purposefully inducing inflammatory cell apoptosis could speed the process of inflammation resolution 118 . Successful inflammation resolution-based therapies for atherosclerosis may necessitate non-oral therapeutic regimens; thus, the primary niche may be short-term therapy after an acute coronary event or in subjects with severe ATVD risk factors who have not been on longterm risk reduction therapy. The foundation of chronic ATVD preventative therapy is risk reduction through cholesterol lowering, mainly by using statins, blood pressure control, treatment of insulin resistance (including lifestyle changes) and elimination of environmental risk factors, notably smoking. However, it takes up to two years for such therapy to show maximum beneficial effects, and even with these therapies, many patients remain at high risk for recurrent disease 119 . In this context, one can envision that safe and effective therapy directed specifically at preventing further plaque progression and promoting plaque regression could substantially lower events during this period. Moreover, therapy directed at improving inflammation resolution would be expected to alter the overall inflammatory milieu of vulnerable plaques in a manner that should improve the effectiveness of conventional, chronic plaque-stabilizing therapies, such as statins. Given the high risk of morbidity and mortality during this period, the benefits of periodic systemic therapy should outweigh the inconvenience.
Summary and conclusions
In industrialized societies, almost all individuals have subclinical atherosclerotic lesions by the time they enter their early twenties 120 . Although only a minority of the lesions in these individuals will progress to cause ATVD, the number of lesions is so high that this progression accounts for the leading cause of morbidity and mortality in this population. Therefore, defining the molecular and cellular processes that cause the transition of subclinical atherosclerotic lesions to dangerous plaques is essential. In this Review, I have discussed recent studies providing evidence that defects in specific molecular and cellular events that normally function to limit or resolve inflammatory processes can account for a substantial portion of this transition. In contemplating how this knowledge can lead to useful therapy, it is important to understand that atherosclerosis progression in general, and defective inflammation resolution in particular, are complex processes, and it is unlikely that only one approach will be effective. Instead, therapeutic approaches that target complementary processes in defective inflammation resolution are likely to have the most success. Fortunately, several of these processes are mediated by common effector molecules (FIG. 2) , which could be feasible targets for both conventional types of drugs and drugs that will require new means of formulation, delivery and tissue targeting. Given the increasingly prevalent pressures of ageing and obesity on ATVD in our society and the rest of the world, even modest progress in this area over the next decade could have a huge beneficial effect.
